On this page

ACETYLCYSTEINE

Prescription ANDA TE AN Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Acetylcysteine
Generic name
Acetylcysteine
Dosage form
Solution
Route
Respiratory (Inhalation)
Marketing category
ANDA · ANDA
Labeler
Fresenius Kabi USA, LLC
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
2
NDC product codes
13
Packages
15
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Acetylcysteine 100 mg/mL 307718 View
Acetylcysteine 200 mg/mL 307718 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Solution
Route of administration
Respiratory (Inhalation)
Presentations
28

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Antidote [EPC] EPC 6 members — no class page
Antidote for Acetaminophen Overdose [EPC] EPC 4 members — no class page
Decreased Respiratory Secretion Viscosity [PE] PE All 52 members
Increased Glutathione Concentration [PE] PE 4 members — no class page
Mucolytic [EPC] EPC 4 members — no class page
Reduction Activity [MoA] MoA 4 members — no class page

Regulatory status

Source: Drugs@FDANDC Directory
Application number
203853
Application type
ANDA · Abbreviated New Drug Application
Approval date
June 21, 2012
Sponsor
ALVOGEN
Products on application
1
Submissions recorded
1
Products approved under application 203853.
Product Trade name Form Strength Ingredient Status TE Flags
203853-001 ACETYLCYSTEINE SOLUTION ACETYLCYSTEINE Prescription AN

Therapeutic equivalence

Source: Orange Book
TE code
AN
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (aerosols)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 203853.
Type No. Action Status Date Review
Original application 1 Approved June 21, 2012 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260522). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260522 HUMAN PRESCRIPTION DRUG · 20250826 HUMAN PRESCRIPTION DRUG · 20240815

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE: Acetylcysteine Solution, USP is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization)

INDICATIONS AND USAGE: Acetylcysteine Solution, USP administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen. It is essential to initiate treatment as soon as possible after the overdose and, in any case, within 24 hours of ingestion.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION General Acetylcysteine Solution 10% and 20% is available in glass vials containing 30 mL. The 20% solution may be diluted to a lesser concentration with either Sodium Chloride Inhalation Solution; Sodium Chloride Injection; or Sterile Water for Injection, or Sterile Water for Inhalation. The 10% solution may be used undiluted. Storage of Opened Vials This product does not contain an antimicrobial agent, and care must be taken to minimize contamination of the sterile solution. If only a portion of the solution in a vial is used, store the remainder in a refrigerator and use for inhalation only within 96 hours. Nebulization — Face Mask, Mouth Piece, Tracheostomy When nebulized into a face mask, mouth piece or tracheostomy, 1 to 10 mL of the 20% solution or 2 to 20 mL of the 10% solution may be given every 2 to 6 hours; the recommended dose for most patients is 3 to 5 mL of the 20% solution or 6 to 10 mL of the 10% solution 3 to 4 times a day. Nebulization — Tent, Croupette In special circumstances it may be necessary to nebulize into a tent or Croupette, and this method of use must be individualized to take into account the available equipment and the patient's particular needs. This form of administration requires very large volumes of the solution, occasionally as much as 300 mL during a single treatment period. If a tent or Croupette must be used, the recommended dose is the volume of acetylcysteine (using 10% or 20%) that will maintain a very heavy mist in the tent or Croupette for the desired period. Administration for intermittent or continuous prolonged periods, including overnight, may be desirable. Direct Instillation When used by direct instillation, 1 to 2 mL of a 10% or 20% solution may be given as often as every hour. When used for the routine nursing care of patients with tracheostomy, 1 to 2 mL of a 10% to 20% solution may be given every 1 to 4 hours by instillation into the tracheostomy. Acetylcysteine may be introduced directly into a particular segment of the bronchopulmonary tree by inserting (under local anesthesia and direct vision) a small plastic catheter into the trachea. Two to 5 mL of the 20% solution may then be instilled by means of a syringe connected to the catheter. Acetylcysteine may also be given through a percutaneous intratracheal catheter. One to 2 mL of the 20% or 2 to 4 mL of the 10% solution every 1 to 4 hours may then be given by a syringe attached to the catheter. Diagnostic Bronchograms For diagnostic bronchial studies, 2 or 3 administrations of 1 to 2 mL of the 20% solution or 2 to 4 mL of the 10% solution should be given by nebulization or by instillation intratracheally, prior to the procedure. Administration of Aerosol Materials Acetylcysteine may be administered using conventional nebulizers made of plastic or glass. Certain materials used in nebulization equipment react with acetylcysteine. The most reactive of these are certain metals (notably iron and copper) and rubber. Where material may come into contact with acetylcysteine solution, parts made of the following acceptable materials should be used: glass, plastic, aluminum, anodized aluminum, chromed metal, tantalum, sterling silver, or stainless steel. Silver may become tarnished after exposure, but this is not harmful to the drug action or to the patient. Nebulizing Gases Compressed tank gas (air) or an air compressor should be used to provide pressure for nebulizing the solution. Oxygen may also be used but should be used with usual precautions in patients with severe respiratory disease and CO 2 retention. Apparatus Acetylcysteine is usually administered as fine nebulae, and the nebulizer used should be capable of providing optimal quantities of a suitable range of particle sizes. Commercially available nebulizers will produce nebulae of acetylcysteine satisfactory for retention in the respiratory tract. Most of the nebulizers tested will supply a high proportion of the drug solution as particles o …

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Acetylcysteine solution is contraindicated in those patients who are sensitive to it.

CONTRAINDICATIONS There are no contraindications to oral administration of acetylcysteine in the treatment of acetaminophen overdose.

WARNINGS After proper administration of acetylcysteine solution, an increased volume of liquified bronchial secretions may occur. When cough is inadequate, the airway must be maintained open by mechanical suction if necessary. Where there is a mechanical block due to foreign body or local accumulation, the airway should be cleared by endotracheal aspiration, with or without bronchoscopy. Asthmatics under treatment with acetylcysteine solution should be watched carefully. Most patients with bronchospasm are quickly relieved by the use of a bronchodilator given by nebulization. If bronchospasm progresses, the medication should be discontinued immediately.

WARNINGS Generalized urticaria has been observed rarely in patients receiving oral acetylcysteine for acetaminophen overdose. If this occurs or other allergic symptoms appear, treatment with acetylcysteine should be discontinued unless it is deemed essential and the allergic symptoms can be otherwise controlled. If encephalopathy due to hepatic failure becomes evident, acetylcysteine treatment should be discontinued to avoid further administration of nitrogenous substances. There are no data indicating that acetylcysteine influences hepatic failure, but this remains a theoretical possibility.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS: Adverse effects have included stomatitis, nausea, vomiting, fever, rhinorrhea, drowsiness, clamminess, chest tightness, and bronchoconstriction. Clinically overt acetylcysteine induced bronchospasm occurs infrequently and unpredictably even in patients with asthmatic bronchitis or bronchitis complicating bronchial asthma. Acquired sensitization to acetylcysteine has been reported rarely. Reports of sensitization in patients have not been confirmed by patch testing. Sensitization has been confirmed in several inhalation therapists who reported a history of dermal eruptions after frequent and extended exposure to acetylcysteine. Reports of irritation to the tracheal and bronchial tracts have been received and although hemoptysis has occurred in patients receiving acetylcysteine such findings are not uncommon in patients with bronchopulmonary disease and a causal relationship has not been established.

ADVERSE REACTIONS: Oral administration of acetylcysteine, especially in the large doses needed to treat acetaminophen overdose, may result in nausea, vomiting and other gastrointestinal symptoms. Rash with or without mild fever has been observed rarely.

Drug Interactions

openFDA Drug Labeling

Drug Interactions Drug stability and safety of acetylcysteine when mixed with other drugs in a nebulizer have not been established.

Description

openFDA Drug Labeling

DESCRIPTION Acetylcysteine solution is for inhalation (mucolytic agent) or oral administration (acetaminophen antidote), and available as sterile, unpreserved solutions (not for injection). Acetylcysteine is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. Chemically, it is N-acetyl-L-cysteine. The compound is a white crystalline powder which melts at 104°−110°C and has a very slight odor. The structural formula for acetylcysteine is as follows: Molecular weight: 163.19 Each mL of the 10% solution contains acetylcysteine 100 mg; edetate disodium, dihydrate 0.25 mg. Each mL of the 20% solution contains acetylcysteine 200 mg; edetate disodium, dihydrate 0.5 mg. The solutions also contain sodium hydroxide and may contain hydrochloric acid for pH adjustment, pH 7.0 (6.0 to 7.5). Acetylcysteine Solution, USP is oxygen sensitive. Acetylcysteine As A Mucolytic Agent structural formula acetylcysteine

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Acetylcysteine Solution, USP is available in rubber stoppered glass vials containing 4, 10, or 30 mL. The 20% solution may be diluted to a lesser concentration with either Sodium Chloride for Injection, Sodium Chloride for Inhalation, Sterile Water for Injection, or Sterile Water for Inhalation. The 10% solution may be used undiluted. Acetylcysteine is sterile, not for injection and can be used for inhalation (mucolytic agent) or oral administration (acetaminophen antidote). It is available as follows: Acetylcysteine 10% solution (100 mg acetylcysteine per mL). Sterile, not for injection. Product No. NDC No. Strength 695104 63323-695-04 10% (100 mg/mL) 4 mL 5 mL vials packed in carton of twenty five 693110 63323-693-10 10% (100 mg/mL) 10 mL 10 mL vials packed in carton of three, plastic dropper 691130 63323-691-30 10% (100 mg/mL) 30 mL 30 mL vials packed in carton of three Acetylcysteine 20% solution (200 mg acetylcysteine per mL). Sterile, not for injection. Product No. NDC No. Strength 694104 63323-694-04 20% (200 mg/mL) 4 mL 5 mL vials packed in carton of twenty five 692110 63323-692-10 20% (200 mg/mL) 10 mL 10 mL vials packed in carton of three, plastic dropper 690130 63323-690-30 20% (200 mg/mL) 30 mL 30 mL vials packed in carton of three STORAGE: Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) (see USP Controlled Room Temperature). Store in refrigerator 2° - 8°C (36° - 46°F) after opening. Acetylcysteine does not contain an antimicrobial agent, and care must be taken to minimize contamination of the sterile solution. Dilutions of acetylcysteine should be used freshly prepared and utilized within one hour. If only a portion of the solution in a vial is used, store the remaining undiluted portion in a refrigerator and use within 96 hours.

Adverse event reports

Source: openFDA FAERS
9,372
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: ACETYLCYSTEINE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
42494-435-25 42494-435 Cameron Pharmaceuticals 25 VIAL in 1 CARTON (42494-435-25) / 4 mL in 1 VIAL August 21, 2025
42494-436-25 42494-436 Cameron Pharmaceuticals 25 VIAL in 1 CARTON (42494-436-25) / 4 mL in 1 VIAL August 21, 2025
63323-690-30 63323-690 Fresenius Kabi USA, LLC 3 VIAL in 1 CARTON (63323-690-30) / 30 mL in 1 VIAL (63323-690-22) September 1, 2012
63323-690-44 63323-690 Fresenius Kabi USA, LLC 3 VIAL in 1 CARTON (63323-690-44) / 30 mL in 1 VIAL (63323-690-41) September 1, 2012
63323-691-30 63323-691 Fresenius Kabi USA, LLC 3 VIAL in 1 CARTON (63323-691-30) / 30 mL in 1 VIAL (63323-691-22) March 31, 2014
63323-692-10 63323-692 Fresenius Kabi USA, LLC 3 VIAL in 1 CARTON (63323-692-10) / 10 mL in 1 VIAL (63323-692-22) September 1, 2012
63323-693-10 63323-693 Fresenius Kabi USA, LLC 3 VIAL in 1 CARTON (63323-693-10) / 10 mL in 1 VIAL (63323-693-22) March 31, 2014
63323-694-04 63323-694 Fresenius Kabi USA, LLC 25 VIAL in 1 CARTON (63323-694-04) / 4 mL in 1 VIAL (63323-694-22) September 1, 2012
63323-694-44 63323-694 Fresenius Kabi USA, LLC 25 VIAL in 1 CARTON (63323-694-44) / 4 mL in 1 VIAL (63323-694-41) September 1, 2012
63323-695-04 63323-695 Fresenius Kabi USA, LLC 25 VIAL in 1 CARTON (63323-695-04) / 4 mL in 1 VIAL (63323-695-22) March 31, 2014
0409-3307-03 0409-3307 Hospira, Inc. 3 VIAL in 1 CARTON (0409-3307-03) / 30 mL in 1 VIAL (0409-3307-11) April 30, 2005
0409-3308-03 0409-3308 Hospira, Inc. 3 VIAL in 1 CARTON (0409-3308-03) / 30 mL in 1 VIAL (0409-3308-11) June 1, 2005
70069-018-25 70069-018 Somerset Therapeutics, LLC 25 VIAL in 1 CARTON (70069-018-25) / 4 mL in 1 VIAL (70069-018-01) March 4, 2025
70069-019-25 70069-019 Somerset Therapeutics, LLC 25 VIAL in 1 CARTON (70069-019-25) / 4 mL in 1 VIAL (70069-019-01) March 4, 2025
70069-020-03 70069-020 Somerset Therapeutics, LLC 3 VIAL in 1 CARTON (70069-020-03) / 30 mL in 1 VIAL (70069-020-01) March 4, 2025
42494-435 42494-435 Cameron Pharmaceuticals — August 21, 2025
42494-436 42494-436 Cameron Pharmaceuticals — August 21, 2025
63323-690 63323-690 Fresenius Kabi USA, LLC — September 1, 2012
63323-691 63323-691 Fresenius Kabi USA, LLC — March 31, 2014
63323-692 63323-692 Fresenius Kabi USA, LLC — September 1, 2012
63323-693 63323-693 Fresenius Kabi USA, LLC — March 31, 2014
63323-694 63323-694 Fresenius Kabi USA, LLC — September 1, 2012
63323-695 63323-695 Fresenius Kabi USA, LLC — March 31, 2014
0409-3307 0409-3307 Hospira, Inc. — April 30, 2005
0409-3308 0409-3308 Hospira, Inc. — June 1, 2005
70069-018 70069-018 Somerset Therapeutics, LLC — March 4, 2025
70069-019 70069-019 Somerset Therapeutics, LLC — March 4, 2025
70069-020 70069-020 Somerset Therapeutics, LLC — March 4, 2025

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.